| Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease. | |
| | |
MedLine Citation:
|
PMID: 20708813 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: AST-120, an oral adsorbent currently on-label only in Asian countries with phase III trials ongoing in the US, slows renal disease progression in patients with diabetes and advanced-stage chronic kidney disease (CKD). The objective of this study is to evaluate the cost-effectiveness of using AST-120 to treat patients with type 2 diabetes and advanced-stage CKD. METHODS: We used Markov model simulating the progression of diabetic nephropathy. Data were obtained from randomized trials estimating the progression of diabetic nephropathy with and without AST-120, and published literature. The base population was patients 60 years of age with type 2 diabetes and Stages 3 and 4 CKD. RESULTS: Treating patients with diabetes and advanced-stage CKD was found to be a dominant strategy, and quality of life improved further and more money was saved (0.22 quality-adjusted life years [QALYs] and $15,019 per patient) using AST-120 than the control strategy. Sensitivity analysis results were robust with regard to cost, adherence, and quality of life associated with AST-120 therapy, as well as age at diagnosis. The model was relatively sensitive to the effectiveness of AST-120. CONCLUSIONS: Treating patients with type 2 diabetes and advanced-stage CKD with AST-120 appears to extend life and reduce costs. |
| | |
Authors:
|
Yasuaki Hayashino; Shunichi Fukuhara; Tadao Akizawa; Yasushi Asano; Takafumi Wakita; Yoshihiro Onishi; Kiyoshi Kurokawa; |
Related Documents
:
|
9476153 - Using the world wide web--a new approach to risk identification of diabetes mellitus. 19335903 - Economic burden of diabetes mellitus in the who african region. 20547683 - Short-term sprint interval training increases insulin sensitivity in healthy adults but... |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2010-08-13 |
Journal Detail:
|
Title: Diabetes research and clinical practice Volume: 90 ISSN: 1872-8227 ISO Abbreviation: Diabetes Res. Clin. Pract. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2010-10-12 Completed Date: 2011-02-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8508335 Medline TA: Diabetes Res Clin Pract Country: Ireland |
Other Details:
|
Languages: eng Pagination: 154-9 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
Department of Epidemiology and Healthcare Research, Kyoto University Graduate School of Medicine, Yoshida, Kyoto 606-8501, Japan. hayasino-y@umin.net |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Aged Carbon / administration & dosage, economics, therapeutic use* Cost of Illness Cost-Benefit Analysis Creatinine / metabolism Diabetes Mellitus, Type 2 / complications, drug therapy*, economics Diabetic Nephropathies / drug therapy*, economics, prevention & control Hemoglobin A, Glycosylated / metabolism Humans Kidney Failure, Chronic / mortality, prevention & control Oxides / administration & dosage, economics, therapeutic use* Quality of Life Renal Insufficiency, Chronic / complications, drug therapy, prevention & control |
| Chemical | |
Reg. No./Substance:
|
0/Hemoglobin A, Glycosylated; 0/Oxides; 60-27-5/Creatinine; 7440-44-0/Carbon; 90597-58-3/AST 120 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: DPP-4 inhibitors: what may be the clinical differentiators?
Next Document: Incretin action maintains insulin secretion, but not hepatic insulin action, in people with impaired...